Prenetics Global CEO Touts IM8 Breakout Growth, Guides $180M-$200M Revenue at Conference

IM8 drove a breakout year: Prenetics reported about $92M in 2025 revenue while its IM8 DTC supplements brand reached $120M ARR, scaled from ~$581k first-month revenue to ~$10M monthly by Dec‑2025 and ended the year at 63% gross margin; management guides $180M–$200M for 2026 and expects gross margins at or above 60%.
Portfolio simplification and strong liquidity: Management sold non-core assets (ACT, Europa, Insighta) to focus on IM8, has roughly $160M in liquid assets, zero debt, and says it has a clear roadmap to profitability by Q4‑2027 (ACT sale $72M with ~$46M received, Insighta ~$70M cash).
Capital-allocation moves and risk posture: Prenetics holds about 510 Bitcoin (has stopped buying) and announced a $40M share buyback (total up to $42.75M including insider purchases), while planning heavy marketing investment (about 45–50% of revenue) and three clinical trials including one with the Mayo Clinic.
Prenetics Global (NASDAQ:PRE) CEO and co-founder Danny Yeung told investors the company delivered what he described as a “breakout growth story” in 2025, driven by the rapid expansion of its IM8 direct-to-consumer supplements business and a broader strategic shift to focus on that brand.
2025 performance and IM8 ramp
Yeung said Prenetics generated approximately $92 million in full-year 2025 revenue, inclusive of multiple business units. He attributed the results largely to IM8, which he said reached $120 million in annual recurring revenue (ARR) in its first full year of operations and ended 2025 at 63% gross margins.
According to Yeung, IM8 launched in December 2024 and scaled quickly. He said the brand’s first-month revenue was about $581,000 and grew to $10 million in monthly revenue by December 2025. He characterized the growth as unusually rapid for the vitamins and supplements category.
Strategic transformation and balance sheet
Yeung said Prenetics has divested non-core assets to concentrate on IM8 and believes it now has “a very clear roadmap to profitability by Q4 of 2027.” He also emphasized the company’s liquidity position, stating Prenetics has approximately $160 million in liquid assets and zero debt.
He outlined several transactions completed as part of the portfolio simplification:
ACT was sold in October for $72 million in cash, and Yeung said Prenetics received approximately $46 million of that amount.
Europa was sold in an all-stock transaction for up to $13 million.
The company sold its entire stake in Insighta to Tencent for $70 million in cash, which Yeung said occurred “last month.”
He said the divestments were driven by IM8’s growth opportunity and management’s view that capital could be deployed more effectively to expand the IM8 business.
Yeung said IM8 ships to 31 countries and has been international from the start. He stated the U.S. represents about 40% of the business, followed by Canada, the U.K., Australia, and Singapore. He also said that in 2025 IM8 generated roughly $60 million in revenue, with about $24 million coming from the U.S., and argued the U.S. market alone could support $150 million to $200 million in revenue.
Discussing the customer profile, Yeung said IM8 is not only for athletes. He described the typical customer as 30 to 60 years old, in the top 10% of household incomes, and looking for a “clean,” “third-party tested,” U.S.-made product without the need to manage multiple pills.
He shared several direct-to-consumer metrics from full-year 2025, including average order value of about $110, customer acquisition cost (CAC) of $130, and an estimated 24-month lifetime value (LTV) of about $480. He also said IM8 is 100% online, with 98% of transactions on its own website and 2% on Amazon.
Yeung said the company introduced a three-month purchase option in the quarter, which he said increased average order value to approximately $233 while also increasing CAC. He added that IM8 has an 80% subscription rate among new customers, contributing to what he described as predictable recurring revenue.
Brand ambassadors, products, and 2026 outlook
Yeung highlighted IM8’s brand-building strategy, including co-founder David Beckham and additional athlete partnerships. He said tennis player Aryna Sabalenka joined in June and that British F1 driver Ollie Bearman was recently announced as an ambassador; Yeung added that all three are also shareholders in Prenetics. He also pointed to social media performance, citing an Instagram video that generated 233 million views, and said the company holds in-person events in cities such as Miami, London, and New York to connect with its community and generate content.
On the product side, Yeung said IM8 has kept its lineup simple, centered on two powder-based offerings: Daily Ultimate Essentials and Daily Ultimate Longevity, which together are marketed as the “Beckham Stack.” He said the longevity product launched in October and helped lift average order value from roughly $110 to $150 “pretty much overnight.” He also discussed an upgraded “Daily Ultimate Essentials PRO,” saying development took roughly six to nine months and included higher clinical dosages for certain ingredients and two new flavors.
For 2026, Yeung issued revenue guidance of approximately $180 million to $200 million and said the company expects to maintain or potentially increase gross margin above 60% as scale improves purchasing leverage. He said growth initiatives include expanding beyond Meta and Google into channels such as TikTok Shop, YouTube, and AppLovin; launching localized marketing in additional countries; and releasing two new products by year-end. In the Q&A, he said those new products were not included in the 2026 guidance.
Bitcoin holdings and share repurchase
Yeung addressed the company’s Bitcoin position, stating Prenetics began purchasing Bitcoin in June 2025 and now holds roughly 510 Bitcoin. He said the company stopped buying Bitcoin on December 4 and does not plan to buy more, describing it as a distraction. He said the holdings are treated as a treasury asset and could be sold if needed.
He also said Prenetics announced a $40 million share buyback roughly two weeks prior and has begun executing it. In addition, he said the management team has made $2.75 million of open-market purchases over the last two quarters, bringing the total planned and executed commitment he cited to up to $42.75 million for share repurchases.
Looking ahead, Yeung said the company is increasing investment in growth, including plans to run three clinical trials—one involving the Mayo Clinic—and expects marketing spend to run about 45% to 50% of revenue as it invests in brand and customer acquisition.
About Prenetics Global (NASDAQ:PRE)
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.